PERIPHERAL BLOOD CYTOGENETIC MONITORING IN AZACITIDINE-TREATED PATIENTS WITH HIGH-RISK MDS
In this single-center retrospective analysis, the response of 76 patients with high-risk myelodysplastic syndrome (MDS) treated with azacitidine (AZA) was reviewed, especially the cytogenetic response (CGR) to determine the response to treatment and the possible impact of karyotype evolution (KE) on the course of the disease. So far, the only treatment option with curative potential […]
